203 related articles for article (PubMed ID: 14742761)
21. Therapeutic monitoring of warfarin: the appropriate response marker.
Costa IM; Soares PJ; Afonso M; Ratado P; Lanaot JM; Falcão AC
J Pharm Pharmacol; 2000 Nov; 52(11):1405-10. PubMed ID: 11186249
[TBL] [Abstract][Full Text] [Related]
22. Poor correlation of supratherapeutic international normalised ratio and vitamin K-dependent procoagulant factor levels during warfarin therapy.
Sarode R; Rawal A; Lee R; Shen YM; Frenkel EP
Br J Haematol; 2006 Mar; 132(5):604-7. PubMed ID: 16445834
[TBL] [Abstract][Full Text] [Related]
23. A comparison of two intensities of warfarin for the prevention of recurrent thrombosis in patients with the antiphospholipid antibody syndrome.
Crowther MA; Ginsberg JS; Julian J; Denburg J; Hirsh J; Douketis J; Laskin C; Fortin P; Anderson D; Kearon C; Clarke A; Geerts W; Forgie M; Green D; Costantini L; Yacura W; Wilson S; Gent M; Kovacs MJ
N Engl J Med; 2003 Sep; 349(12):1133-8. PubMed ID: 13679527
[TBL] [Abstract][Full Text] [Related]
24. Warfarin monitoring in antiphospholipid syndrome and lupus anticoagulant.
Crowl A; Schullo-Feulner A; Moon JY
Ann Pharmacother; 2014 Nov; 48(11):1479-83. PubMed ID: 25104566
[TBL] [Abstract][Full Text] [Related]
25. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy.
Harrison L; Johnston M; Massicotte MP; Crowther M; Moffat K; Hirsh J
Ann Intern Med; 1997 Jan; 126(2):133-6. PubMed ID: 9005747
[TBL] [Abstract][Full Text] [Related]
26. Performance of prothrombin-proconvertin time as a monitoring test of oral anticoagulation therapy.
Haraldsson HM; Onundarson PT; Einarsdóttir KA; Guõmundsdóttir BR; Pétursson MK; Pálsson K; Kristinsson A
Am J Clin Pathol; 1997 Jun; 107(6):672-80. PubMed ID: 9169664
[TBL] [Abstract][Full Text] [Related]
27. Critical role of factors II and X during coumarin anticoagulation and their combined measurement with a new Fiix-prothrombin time.
Gudmundsdottir BR; Francis CW; Bjornsdottir AM; Nellbring M; Onundarson PT
Thromb Res; 2012 Oct; 130(4):674-81. PubMed ID: 22225856
[TBL] [Abstract][Full Text] [Related]
28. Reversal of elevated international normalized ratios and bleeding with low-dose recombinant activated factor VII in patients receiving warfarin.
Dager WE; King JH; Regalia RC; Williamson D; Gosselin RC; White RH; Tharratt RS; Albertson TE
Pharmacotherapy; 2006 Aug; 26(8):1091-8. PubMed ID: 16863486
[TBL] [Abstract][Full Text] [Related]
29. A feasibility study of continuing dose-reduced warfarin for invasive procedures in patients with high thromboembolic risk.
Larson BJ; Zumberg MS; Kitchens CS
Chest; 2005 Mar; 127(3):922-7. PubMed ID: 15764777
[TBL] [Abstract][Full Text] [Related]
30. [Complications and risks associated with an anticoagulation therapy combining low molecular weight heparin and Warfarin after total replacement of large joints--our experience].
Míka P; Behounek J; Skoták M; Nevsímal L
Acta Chir Orthop Traumatol Cech; 2004; 71(4):237-44. PubMed ID: 15456102
[TBL] [Abstract][Full Text] [Related]
31. Supratherapeutic international normalized ratio due to reduced vitamin K intake secondary to prolonged vomiting in a patient on warfarin.
Reaves AB; Clarke CJ; Tillman EM
Ann Pharmacother; 2013 Jun; 47(6):e28. PubMed ID: 23719786
[TBL] [Abstract][Full Text] [Related]
32. Evaluation of warfarin management with international normalized ratio self-testing and online remote monitoring and management plus low-dose vitamin k with genomic considerations: a pilot study.
Bussey HI; Bussey M; Bussey-Smith KL; Frei CR
Pharmacotherapy; 2013 Nov; 33(11):1136-46. PubMed ID: 24038412
[TBL] [Abstract][Full Text] [Related]
33. Anticoagulation with r-hirudin in regular haemodialysis with heparin-induced thrombocytopenia (HIT II). The first long-term application of r-hirudin in a haemodialysis patient.
Nowak G; Bucha E; Brauns I; Czerwinski R
Wien Klin Wochenschr; 1997 May; 109(10):354-8. PubMed ID: 9200807
[TBL] [Abstract][Full Text] [Related]
34. Mechanism of the anticoagulant effect of warfarin as evaluated in rabbits by selective depression of individual procoagulant vitamin K-dependent clotting factors.
Zivelin A; Rao LV; Rapaport SI
J Clin Invest; 1993 Nov; 92(5):2131-40. PubMed ID: 8227329
[TBL] [Abstract][Full Text] [Related]
35. Heparin-induced thrombocytopenia: a ten-year retrospective.
Warkentin TE
Annu Rev Med; 1999; 50():129-47. PubMed ID: 10073268
[TBL] [Abstract][Full Text] [Related]
36. A factor VII-based method for the prediction of anticoagulant response to warfarin.
Ooi QX; Wright DFB; Isbister GK; Duffull SB
Sci Rep; 2018 Aug; 8(1):12041. PubMed ID: 30104739
[TBL] [Abstract][Full Text] [Related]
37. Factor X and factor II activity levels do not always agree in warfarin-treated lupus anticoagulant patients.
Rosborough TK; Jacobsen JM; Shepherd MF
Blood Coagul Fibrinolysis; 2010 Apr; 21(3):242-4. PubMed ID: 20182349
[TBL] [Abstract][Full Text] [Related]
38. Lepirudin is a safe and effective anticoagulant for patients with heparin-associated antiplatelet antibodies.
Mudaliar JH; Liem TK; Nichols WK; Spadone DP; Silver D
J Vasc Surg; 2001 Jul; 34(1):17-20. PubMed ID: 11436069
[TBL] [Abstract][Full Text] [Related]
39. Variability in the international normalised ratio (INR) in patients with antiphospholipid syndrome and positive lupus anticoagulant: should the INR targets be higher?
Baquero-Salamanca M; Téllez-Arévalo AM; Calderon-Ospina C
BMJ Case Rep; 2015 Apr; 2015():. PubMed ID: 25858939
[TBL] [Abstract][Full Text] [Related]
40. Bivalirudin anticoagulation for a patient with hypercoagulable immune syndromes undergoing mitral valve surgery.
Cain RL; Spiess BD; Nelson M; Deanda A; McCarthy HL; Green JA
Ann Thorac Surg; 2006 Jun; 81(6):2308-10. PubMed ID: 16731183
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
